NEW INSIGHTS INTO CHRONIC FATIGUE SYNDROME
NIH GUIDE, Volume 23, Number 29, August 5, 1994
PA NUMBER: PA-94-092
P.T. 34
Keywords:
Chronic Fatigue
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Mental Health
PURPOSE
The National Institute of Allergy and Infectious Diseases (NIAID),
National Institute of Arthritis and Musculoskeletal and Skin Diseases
(NIAMS), and National Institute of Mental Health (NIMH) invite
investigator-initiated research grant applications to support research
on the etiology, natural history, and pathogenesis of chronic fatigue
syndrome (CFS).
HEALTHY PEOPLE 2000
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas. This program
announcement, New Insights into Chronic Fatigue Syndrome, is related to
the priority area of chronic disabling diseases. Potential applicants
may obtain a copy of "Healthy People 2000" (Full Report: Stock No.
017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No.
017-001-00473-1) through the Superintendent of Documents, Government
Printing Office, Washington, DC 20402-0325 (telephone 202-783-3238).
ELIGIBILITY REQUIREMENTS
Applications may be submitted by domestic and foreign, for-profit and
non-profit organizations, public and private, such as universities,
colleges, hospitals, laboratories, units of State and local
governments, and eligible agencies of the Federal government.
Applications from minority individuals and women are encouraged.
Foreign institutions are not eligible for First Independent Research
Support and Transition (FIRST) (R29) awards.
MECHANISM OF SUPPORT
Traditional research project grant (R01) and FIRST award (R29)
applications may be submitted in response to this program announcement.
The R01 mechanism can be used to support small studies. Funds and time
requested should be appropriate for the research proposed.
RESEARCH OBJECTIVES
Background
Chronic fatigue syndrome (CFS) is a multisystem syndrome thought to be
triggered by acute infectious illness and characterized by months of
debilitating fatigue frequently associated with myalgia, headache, sore
throat, low grade fever, cognitive complaints, gastrointestinal
symptoms, and tender lymph nodes. There have been reports of
immunologic and, more recently, neuroendocrine parameters that differ
in CFS patients as a group compared to healthy controls. However, no
single marker has been identified that can be used to diagnose the
syndrome. CFS is diagnosed three to four times more frequently in
women than in men and about 10 times more often in white Americans than
in other American population groups. The cause and pathogenic
mechanisms of the illness are unknown.
Research Objectives and Experimental Approaches
Well-designed studies are needed to provide a better understanding of
CFS and to develop diagnostic and intervention strategies. Studies
should include appropriate sample sizes and test biologically rational
hypotheses concerning etiology, natural history or pathogenesis of the
syndrome. Applications for small studies that explore new ideas are
also encouraged and could provide the basis for submission of a
subsequent larger grant application.
Clinical epidemiologic studies may identify factors that affect
prognosis or that are associated with susceptibility, including
immunogenetic, behavioral, environmental, and psychosocial factors.
Several observations reported in the literature merit further study to
determine their biologic and/or epidemiologic basis, generalizability
and/or role in CFS. These include, but are not limited to:
o lymphocyte patterns suggestive of immune activation (e.g.,
alterations in T-cell subsets number and function, altered cytokine
levels and function)
o low levels of cortisol and corticotropin-releasing hormone in CFS
patients in the absence of documented adrenal-hypothalamic axis
dysfunction attributable to other causes
o increased frequency of sleep disturbances (hypersomnia or insomnia)
o overlapping symptomatology with fibromyalgia
o low tolerance to physical exertion manifested by prolonged
generalized fatigue after very moderate exercise
o demographic risk factors (gender, age, race, socioeconomic class)
o reactivation of latent viruses (e.g., use of sensitive and specific
assays to measure viral reactivation in carefully defined and
controlled specimens)
o increased frequency of psychiatric diagnoses in CFS patients (except
those that would exclude an individual from the CFS case definition)
o increased frequency of atopy in CFS patients compared with the U.S.
population as a whole
o highly active lifestyle prior to onset of CFS
Multidisciplinary studies and collaboration among investigators with
expertise in appropriate disciplines are encouraged. When
investigators are at different institutions, individual R01
applications may include consortium arrangements.
Collaborative arrangements with on-going studies that provide patient
populations, specimens and data are encouraged. Such arrangements
should be clearly delineated in the application.
The methodologies and personnel involved in statistical/epidemiological
analyses should be described in the application and evident in the
study design. The hypothesis(es) to be tested should be clearly
stated. The constructs and measurements to be used operationally to
obtain statistically and biologically meaningful results should be
clearly defined and enumerated.
The value of studies of patients or their specimens will be directly
related to the care exercised in selection and initial characterization
of cases and controls. A detailed description of case recruitment
procedures, the criteria to be used for case definition and the manner
in which the criteria are to be applied must be included. Similar care
should be given to descriptions of enrollment of comparison groups.
Investigators are encouraged to use the CFS case definition as
initially presented in Holmes, et al. (Annals of Internal Medicine:
108, 387-389, 1988) and subsequently modified in Schluederberg, et al.
(Annals of Internal Medicine: 117, 325-331, 1992) and in Fukuda, et al
(in press). If other case definitions are proposed, they should be
clearly defined and the rationale for their choice clearly delineated.
Parameter Measurements
Applications to estimate the frequency of physiological or behavioral
variables or responses or to address other quantitative aspects in
relevant populations should pay particular attention to sample sizes
required to attain the degree of precision sought or needed for
statistically and biologically meaningful results. The reliability and
validity of markers chosen for measurement should be demonstrated.
Applications attempting to examine interrelationships among two or more
separate factors are encouraged to the extent that the types and
numbers of subjects are sufficient for such comparisons.
The measurement of cellular phenotypes, cytokine activities and other
immunological and viral markers are highly dependent on the assay
system chosen and its execution. Thus, it is very important that
applicants clearly define the methodologies to be used, the rationale
for choosing that methodology and for validating results as well as
methods of collection, processing, and storage of samples. When
conflicting results have been reported in the literature, applicants
should provide possible explanations for such variability and indicate
how their approach might resolve the issue.
STUDY POPULATIONS
INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS
It is the policy of the NIH that women and members of minority groups
and their subpopulations must be included in all NIH supported
biomedical and behavioral research projects involving human subjects,
unless a clear and compelling rationale and justification is provided
that inclusion is inappropriate with respect to the health of the
subjects or the purpose of the research. This new policy results from
the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43)
and supersedes and strengthens the previous policies (Concerning the
Inclusion of Women in Study Populations, and Concerning the Inclusion
of Minorities in Study Populations) which have been in effect since
1990. The new policy contains some new provisions that are
substantially different from the 1990 policies.
All investigators proposing research involving human subjects should
read the "NIH Guidelines For Inclusion of Women and Minorities as
Subjects in Clinical Research", which have been published in the
Federal Register of March 28, 1994 (FR 59 14508-14513), and reprinted
in the NIH GUIDE FOR GRANTS AND CONTRACTS of March 18, 1994, Volume 23,
Number 11.
Investigators may obtain copies from these sources or from the program
staff or contact persons listed below. Program staff may also provide
additional relevant information concerning the policy.
APPLICATION PROCEDURES
Applications are to be submitted on the grant application form PHS 398
(rev. 9/91) and will be accepted on the standard application deadlines
as indicated in the application kit. Application kits are available at
most institutional offices of sponsored research and may be obtained
from the Office of Grants Information, Division of Research Grants,
National Institutes of Health, Westwood Building, Room 449, Bethesda,
MD 20892, telephone (301) 710-0267.
Each application must be identified by checking "YES" on line 2a of the
PHS face page, and the number and title of this announcement must be
typed in section 2a.
FIRST (R29) applications must include at least three sealed letters of
reference attached to the face page of the original application. FIRST
applications submitted without the required number of reference letters
will be considered incomplete and will be returned without review.
The completed original and five legible, single-sided copies of the
application must be sent or delivered to:
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD 20892**
Applicants from institutions that have a General Clinical Research
Center (GCRC) funded by the NIH National Center for Research Resources
may wish to identify the Center as a resource for conducting the
proposed research. If so, a letter of agreement from the GCRC Program
Director must be included in the application material.
REVIEW CONSIDERATIONS
Applications will be assigned on the basis of established PHS referral
guidelines. Applications will be reviewed for scientific and technical
merit by study sections of the Division of Research Grants, NIH, in
accordance with the standard NIH peer review procedures. Following
scientific/technical review, the applications will receive secondary
review by the appropriate national advisory council.
AWARD CRITERIA
Applications will compete for available funds with all other favorably
recommended applications assigned to that ICD. The following will be
considered when making funding decisions: quality of the proposed
project as determined by peer review, program balance among research
areas of the announcement, availability of funds.
INQUIRIES
Written and telephone inquiries are encouraged. The opportunity to
clarify any issues from potential applicants is welcome. Direct
inquiries regarding programmatic issues to:
Susan Spring, Ph.D.
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
Solar Building, Room 3A14
6003 Executive Boulevard MSC 7630
Bethesda, MD 20892-7630
Telephone: (301) 496-7453
FAX: (301) 496-8030
Susana A. Serrate-Sztein, Ph.D
Arthritis Branch
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Westwood Building, Room 405
Bethesda, MD 20892
Telephone: (301) 594-9953
FAX: (301) 594-9673
Fred Altman, Ph.D.
Basic Prevention and Behavioral Medicine Research Branch
National Institute of Mental Health
Parklawn Building, Room 11C06
Rockville, MD 20857
Telephone: (301) 443-4337
FAX: (301) 443-4822
Direct inquiries regarding fiscal matters to:
Ms. Victoria Putprush
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Solar Building, Room 4B35
6003 Executive Boulevard MSC 7610
Bethesda, MD 20892-7610
Telephone: (301) 496-7075
FAX: (301) 480-3780
Mr. Joseph L. Brown
Grants Management Branch
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Westwood Building, Room 722C
Bethesda, MD 20892
Telephone: (301) 594-9970
FAX: (301) 594-9950
Mr. Bruce Ringler
Grants Management Branch
National Institute of Mental Health
Parklawn Building, Room 7C08
5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 443-3065
AUTHORITY AND REGULATIONS
This program is described in the Catalog of Federal Domestic Assistance
No. 93.856, Microbiology and Infectious Disease Research, No. 93.846,
Arthritis, Musculoskeletal, and Skin Diseases Research and No. 93.242,
Mental Health Research. Awards are made under authorization of the
Public Health Service Act, Title IV, Part A (Public Law 78-410, as
amended by Public Law 99-158, 42 USC 241 and 285) and administered
under PHS grant policies and Federal Regulations at 42 CFR Part 52 and
45 CFR Part 74. This program is not subject to the intergovernmental
review requirements of Executive Order 12372 or Health Systems Agency
review.
.